Panel talk about Inify’s fourth quarter 2023

Listen to CEO Fredrik Palm and Sales & Marketing Manager Maria Holmberg in this panel talk, moderated by Ole Eikeland, where they talk about the immediate effects of using Inify's services, where customers have been able to shorten time for result to patients from 21 to 7 days, how word-of-mouth marketing has led to incoming calls plus how AI supports the patologists making the cancer diagnosis.

Inify Laboratories saw important pieces fall into place during the fourth quarter of 2023, the foremost being the attainment of accreditation as a medical laboratory. This paved the way for making Inify’s diagnostic service fully available to both private and public healthcare providers resulting in considerable sales growth.

This and other highlights of the quarter are discussed in a panel talk led by Ole Eikeland, where Inify's CEO Fredrik Palm and Sales & Marketing Manager Maria Holmberg share their thoughts both on the past months and the future. Link to the panel talk is available here.  
 
For more information, contact CEO Fredrik Palm, fredrik.palm@inify.com, or visit https://www.inify.com.

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate. The concept is scalable and can be extended to other diagnoses. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist. The report is assisted by Inify's own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system. The company, based in Sweden, became independent in 2022 through a spin-off from ContextVision, with 40 years of experience within digital imaging for medical applications. It is listed on Euronext Growth Oslo under the ticker INIFY.

Tags: